Hint mode is switched on Switch off
For swift navigation between sections

Nurix Therapeutics

PDF download

Choose all Reset all
Download Cancel
Organization name
Nurix Therapeutics Inc
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Awards

News

11/06/2026 Nurix Therapeutics: Of This Current Report On Form 8k Shall Not Be Deemed To Be “filed” For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (the “exchange Act”), Or Otherwise Subject To The Liability Of That Section, And Shall Not Be Incorporated By Reference Into Any Registration Statement Or Other Document Filed Under The Securities Act Of 1933, As Amended, Or The Exchange Act, Except As Shall Be Expressly Set Forth By Specific Reference In Such Filing. In Addition, The Information Set Forth Under This Item 7.01, Including Exhibit 99.1, Shall Not Be Deemed An Admission As To The Materiality Of Any Information In This Current Report On Form 8k, Other Events, Financial Statements And Exhibits
06/06/2026 Nurix Therapeutics: Of This Current Report On Form 8k, Including Exhibits 99.1 And 99.2, Shall Not Be Deemed To Be “filed” For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (the “exchange Act”), Or Otherwise Subject To The Liability Of That Section, And Shall Not Be Incorporated By Reference Into Any Registration Statement Or Other Document Filed Under The Securities Act Of 1933, As Amended, Or The Exchange Act, Except As Shall Be Expressly Set Forth By Specific Reference In Such Filing. In Addition, The Information Set Forth Under This Item 7.01, Including Exhibits 99.1 And 99.2, Shall Not Be Deemed An Admission As To The Materiality Of Any Information In This Current Report On Form 8k, Financial Statements And Exhibits
12/01/2026 Nurix Therapeutics: Of This Current Report On Form 8k Shall Not Be Deemed To Be “filed” For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (the “exchange Act”), Or Otherwise Subject To The Liability Of That Section, And Shall Not Be Incorporated By Reference Into Any Registration Statement Or Other Document Filed Under The Securities Act Of 1933, As Amended, Or The Exchange Act, Except As Shall Be Expressly Set Forth By Specific Reference In Such Filing. In Addition, The Information Set Forth Under This Item 7.01, Including Exhibits 99.1 And 99.2, Shall Not Be Deemed An Admission As To The Materiality Of Any Information In This Current Report On Form 8k, Financial Statements And Exhibits
22/10/2025 Nurix Therapeutics: Other Events, Financial Statements And Exhibits
03/09/2025 Nurix Therapeutics: Of This Current Report On Form 8k Shall Not Be Deemed To Be “filed” For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (the “exchange Act”), Or Otherwise Subject To The Liability Of That Section, And Shall Not Be Incorporated By Reference Into Any Registration Statement Or Other Document Filed Under The Securities Act Of 1933, As Amended, Or The Exchange Act, Except As Shall Be Expressly Set Forth By Specific Reference In Such Filing. In Addition, The Information Set Forth Under This Item 7.01, Including Exhibit 99.1, Shall Not Be Deemed An Admission As To The Materiality Of Any Information In This Current Report On Form 8k, Financial Statements And Exhibits
All organization news

Documentation

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
II q eng
III q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
III q eng
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • NACE
    *** ***
  • NAICS
    *** ***
  • CIK
    0001549595
  • EIN
    27-0838048
Registration is required to get access.